HOME - Clinical cases - Implantology
 
 
06 August 2026

Non-Surgical Submarginal Instrumentation of Peri-Implant Mucositis With Delivery of Sodium Hypochlorite/Amino Acids and Cross-Linked Hyaluronic Acid: A Randomized Clinical Trial.


This peer-reviewed implantology article summarizes clinical evidence from Clinical oral implants research (2026). It focuses on findings that may help dental professionals evaluate treatment decisions, patient outcomes, or clinical protocols.

Abstract

OBJECTIVES: To evaluate the effects of submarginal instrumentation (SI) with or without adjunctive delivery of sodium hypochlorite (NaOCl)/amino acids and cross-linked hyaluronic acid (xHyA) gel in the treatment of peri-implant mucositis (PM).

MATERIAL AND METHODS: Forty implants supporting single-unit crowns diagnosed with PM in 40 patients were randomly assigned to test (SI + NaOCl/amino acids and xHyA) or control group (SI alone). The primary outcome was mean BoP change. Full-Mouth Plaque Score (FMPS), Full-Mouth Bleeding Score (FMBS), modified plaque index (mPlI), and probing depth (PD) were assessed as secondary outcomes. Clinical parameters were assessed at baseline, 3 and 6 months. Disease resolution was also recorded.

RESULTS: Two patients were lost during follow-up while 38 patients completed the study without adverse effects. After 6 months, all clinical parameters improved statistically significantly in both groups (p < 0.05). The change in mean BoP at 1, 3, and 6 months was 72.2% ± 24.3%, 70.4% ± 24.3%, and 63.0% ± 24.6% for test group and 70.0% ± 19.9%, 66.7% ± 24.8%, and 56.7% ± 30.8% for control group. The mean BoP change in experimental procedure was statistically significant at all investigation time points (p < 0.05). Regarding disease resolution, implants with initial PD ≤ 4 mm did not show differences among groups (p > 0.05); conversely, an initial PD = 5 mm yielded a statistically significant difference (p < 0.05). Disease resolution correlation with test group was statistically significant with a 3.77 odds ratio.

CONCLUSION: Within the limitations of the present study, adjunctive delivery of NaOCl/amino acids and xHyA to SI yielded superior clinical outcomes compared with SI alone in the treatment of PM.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT05926297.

Key takeaway

Key takeaway: Because the evidence comes from a clinical trial design, the findings may be especially useful when comparing treatment approaches in daily practice.

Peer-reviewed source

Vincenzo Iorio-Siciliano, Andrea Blasi, Leopoldo Mauriello, Peter Windisch, Giovanni E Salvi, Anton Sculean, Luca Ramaglia

Clinical oral implants research. 2026

DOI: 10.1111/jcpe.13789

PMID: 41761442

PubMed: https://pubmed.ncbi.nlm.nih.gov/41761442/

Image: Jonathan Borba (Unsplash)

Related articles

To report a fully digital and guided immediate-load All-on-4 protocol conducted in Brazil on a 59-year-old male patient with an edentulous maxilla and a history of oropharyngeal cancer surgery,...


ONEDAYBIOTECH products garner honor as one of the 16th Annual Readers’ Choice Top 25 Implant Products


When placing implants in the mandible or maxilla, it is important for clinicians to understand the process of bone remodeling, the different types of bone, and how these factors can affect the...


Read more

Pre-injection anesthetic spray designed to transform dental injections from a workflow bottleneck into a fast efficient process.


Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the company will hold an Investor Day on Thursday, September 17, from 9:00 a.m.


Former Glidewell Dental CEO brings more than 25 years of leadership experience in organizational transformation, strategy, and workforce development


The CU Anschutz School of Dental Medicine will showcase a wide breadth of educational innovation, faculty development, clinical training and research at three major gatherings this


Dissolves Debris, Inhibits Mercury Release, and Meets EPA Dental Rule Standards


 
 
 
 

 
 
 
 

Most popular

 
 

Events